Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Impact
This bill has the potential to dramatically impact state laws related to healthcare and insurance by establishing new standards for health plans under the New Jersey Individual Health Coverage and Small Employer Health Benefits Programs, as well as the State Health Benefits Program and the School Employees' Health Benefits Program. By setting maximum limits on copayments and removing deductibles for insulin purchases, the legislation intends to ensure that all diabetic patients, regardless of their insurance status, can access the medication they need without excessive costs. The implications of this could spell significant reform in how prescription medications are covered under state health plans.
Summary
Assembly Bill 1439 aims to address the rising costs of insulin which has become a significant burden for many diabetes patients in New Jersey. As insulin prices have soared, with reported increases of up to 700% over two decades, this bill seeks to mandate insurance coverage that facilitates access to this crucial medication. The legislation specifies that health benefit plans must provide insulin coverage without deductibles and limit copayments to a maximum of $50 for a 30-day supply. This provision is designed to alleviate the financial strain on patients who require insulin on a regular basis for their health management.
Contention
Despite its positive intentions, A1439 has generated debate among legislators and health policy advocates. Supporters argue that it is a necessary step to combat the rising costs of insulin, while some critics may view it as an insufficient measure that fails to address the root causes of high medication prices in the pharmaceutical industry. Additionally, there could be concerns regarding how this bill will affect the economics of health insurers, including the potential for increased premiums. The bill also mandates insulin manufacturers to provide annual reports on pricing, which may further fuel discussions about transparency in drug pricing.
Carry Over
Provides that purchase of insulin is not subject to deductible and requires health insurers to limit copayments and coinsurance for insulin.
Carry Over
Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.
Prohibits cost sharing for insulin; provides that an insured shall not be subject to a deductible, copayment, coinsurance or any other cost sharing requirement for the purchase of insulin.
Requires State entities purchase five percent of goods and services from Central Nonprofit Agency; requires Division of Purchase and Property establish training protocols for all purchasing agents; grants Central Nonprofit Agency right of first refusal.
Requires Commissioner of Labor and Workforce Development to conduct study and issue report on impact of artificial intelligence on growth of State's economy.